Allogene Therapeutics Inc. (ALLO)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.
Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript
Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript
Allogene Therapeutics Q2 Earnings Call Highlights
Allogene Therapeutics NASDAQ: ALLO outlined progress across its clinical pipeline during its second-quarter 2026 conference call, highlighting expanded enrollment infrastructure for its pivotal ALPHA3 lymphoma study, recent FDA designations for cema-cel, published renal cell carcinoma data for ALLO-316, and plans to report initial data from the ALLO-329 autoimmune program by year-end.
Why Is Allogene Therapeutics (ALLO) Down 12.2% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1
ALLO posts a narrower Q1 loss, raises its 2026 expense outlook and shares positive interim data from its pivotal ALPHA3 study.
Allogene Therapeutics Q1 Earnings Call Highlights
Allogene Therapeutics NASDAQ: ALLO said its first quarter of 2026 was marked by early clinical progress for its lead allogeneic CAR-T programs and a strengthened cash position following an April financing.
Allogene Therapeutics ends China cell therapy deal with Overland
Allogene Therapeutics said on Wednesday it has ended a key partnership for developing cell therapies in parts of Asia and reworked its equity stake in partner Overland Therapeutics.
ALLO Rises on Strong MRD Clearance With Cema-Cel in ALPHA3 Study
Allogene jumps as cema-cel shows strong MRD clearance and safety in the ALPHA3 study, signaling potential in first-line LBCL treatment.
Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript
Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell Lymphoma Transcript
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q4
ALLO posts a narrower Q4 loss than expected, cuts expenses and advances key CAR-T studies, with cash projected to fund operations into 2028.
Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript
Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call Transcript
